🇺🇸 FDA
Pipeline program

Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)

14130

Phase 3 mab completed

Quick answer

Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) for Retinal Vein Occlusion is a Phase 3 program (mab) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Retinal Vein Occlusion
Phase
Phase 3
Modality
mab
Status
completed

Clinical trials